Corvidia Therapeutics, a Boston, MA-based biotechnology company focused on the development of precision cardiovascular therapies, raised $26m in Series A funding.
The round was co-led by Sofinnova Partners and Apple Tree Partners. In conjunction with the financing, Seth Harrison and Adrien Lemoine, Executive Director, Corporate Development for AstraZeneca, will join Graziano Seghezzi, Partner at Sofinnova Partners, and Seth Harrison, M.D., Managing Partner of Apple Tree Partners, on Corvidia’s Board of Directors.
Co-founded by Chief Executive Officer Michael Davidson, M.D., Rahul Kakkar M.D., Matt Devalaraja, Ph.D., and Ram Aiyar Ph.D., MBA, Corvidia
is pioneering innovative cardiovascular therapies leveraging functional genomics. The company has just licensed a clinical stage compound from AstraZeneca to develop and commercialize COR-001, a monoclonal antibody as its lead therapeutic.
Initially developed by MedImmune, AstraZeneca’s global biologics research and development arm, COR-001 was previously in a Phase 1 study for a different indication.
Corvidia now will use the funds to progress COR-001 into Phase I/II clinical trials during 2016, as well as to advance its preclinical pipeline.